Gyre Therapeutics, Inc. (GYRE) Financials

GYRE Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 162.0 million 25.0 million
Dec. 31, 2025 166.1 million 23.9 million
Sept. 30, 2025 159.4 million 22.0 million
June 30, 2025 152.6 million 23.2 million

GYRE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 3.0 million 2.6 million
Dec. 31, 2025 -5.8 million 4.6 million
Sept. 30, 2025 4.0 million 1.1 million
June 30, 2025 1.8 million 906000

GYRE Net Income

No data available :(

GYRE Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 37.5 million 72000 -
Dec. 31, 2025 52.4 million - 303000
Sept. 30, 2025 40.4 million 539000 1.2 million
June 30, 2025 54.4 million - 1.4 million

GYRE Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 91.3 million
Dec. 31, 2025 102.9 million
Sept. 30, 2025 102.7 million
June 30, 2025 102.7 million

GYRE Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 178000 6.7 million 21.4 million 14.1 million
Dec. 31, 2025 144000 4.8 million 30.5 million 23.8 million
Sept. 30, 2025 683000 2.4 million 19.6 million 15.3 million
June 30, 2025 279000 3.4 million 20.0 million 15.2 million

GYRE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 22.5 million 1.2 million
Dec. 31, 2025 37.2 million 1.7 million
Sept. 30, 2025 30.6 million 1.6 million
June 30, 2025 26.8 million 1.2 million

GYRE Revenue by Segment
Graph available only for paid members. Upgrade to see it.

GYRE

Price: $5.75

52 week price:
5.44
9.42

Payout Ratio Range:
-6400.16%
11221.82%

Earnings Per Share: -0.08 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 610.1 million

Links: